

Glycoscience *for* Human Health

Since 1950, Seikagaku Corporation has pioneered the study of glycoconjugates, biologically essential natural elements that regulate basic activities on the cellular level. It was the first company in the world to begin large-scale production of chondroitin sulfate, a glycoconjugate used in a variety of pharmaceutical products. In 1987, it rolled out a proprietary formulation of sodium hyaluronate, a glycoconjugate prescribed for the treatment of osteoarthritis. Two decades later, sales of this flagship product are still climbing around the world.

Each year, science develops a deeper awareness of the medical potential of glycoconjugates in the newly emerging field of glycoscience. Seikagaku is leveraging its half-century of experience in this area to seek new breakthroughs in a balanced program of original research, international collaboration and licensing. Our purpose is to find and develop novel approaches that lead to significant new products for the medical and healthcare industries—centered on, but not limited to diseases of the joints.

As a leading producer of glycoconjugate-related pharmaceuticals, Seikagaku is recognized internationally for the superior quality of its products. Furthering its role as a pioneer in glycoscience research and development, it hopes to bring new improvements to the quality of life for people everywhere.

CONTENTS

CONSOLIDATED FINANCIAL HIGHLIGHTS . . .	1
A MESSAGE FROM THE PRESIDENT	2
BUSINESS OUTLINE	6
SEGMENT REVIEW	7
GLYSCIENCE	8
R&D ACTIVITIES	9
SIGNIFICANT EVENTS DURING THE YEAR . .	12
FINANCIAL STATEMENTS	13
INDEPENDENT AUDITORS' REPORT	25
BOARD OF DIRECTORS	26
CORPORATE GOVERNANCE	27
SOCIAL CONTRIBUTION	27
ORGANIZATION	28
LABORATORIES AND PLANTS	28
CONSOLIDATED SUBSIDIARIES	28
CORPORATE DATA	29

